{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:02:50Z","timestamp":1791525770225,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002999","name":"Ministerie van Volksgezondheid, Welzijn en Sport","doi-asserted-by":"publisher","award":["SP332956"],"award-info":[{"award-number":["SP332956"]}],"id":[{"id":"10.13039\/501100002999","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40264-025-01638-2","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T13:41:05Z","timestamp":1765460465000},"page":"529-539","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["GP Consultations for Herpes Zoster After COVID-19 Vaccination: A Self-Controlled Cohort Study Based on Electronic Health Record Data from the Netherlands"],"prefix":"10.1007","volume":"49","author":[{"given":"Rana","family":"Jajou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eug\u00e8ne","family":"van Puijenbroek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jetty","family":"Overbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Hek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8965-3224","authenticated-orcid":false,"given":"Florence","family":"van Hunsel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Kant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"issue":"1","key":"1638_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40264-022-01253-5","volume":"46","author":"I Oosterhuis","year":"2023","unstructured":"Oosterhuis I, Scholl J, van Puijenbroek E, Kant A, van Hunsel F. Optimizing safety surveillance for COVID-19 vaccines at the National Pharmacovigilance Centre Lareb: one year of COVID-19 vaccine experience. Drug Saf. 2023;46(1):65\u201375. https:\/\/doi.org\/10.1007\/s40264-022-01253-5.","journal-title":"Drug Saf"},{"issue":"29","key":"1638_CR2","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1016\/j.vaccine.2023.05.053","volume":"41","author":"SC van der Boor","year":"2023","unstructured":"van der Boor SC, Schmitz-de Vries ETJ, Smits D, Scholl JHG, Rolfes L, van Hunsel F. Spontaneously reported adverse events following COVID-19 basic and booster immunizations in the Netherlands. Vaccine. 2023;41(29):4319\u201326. https:\/\/doi.org\/10.1016\/j.vaccine.2023.05.053.","journal-title":"Vaccine"},{"key":"1638_CR3","unstructured":"Kissoon N. Postherpetic neuralgia. UpToDate. 2025. https:\/\/www.uptodate.com\/contents\/postherpetic-neuralgia?search=post%20herpetisch&source=search_result&selectedTitle=1~43&usage_type=default&display_rank=1. Accessed 9 May 2025."},{"key":"1638_CR4","doi-asserted-by":"publisher","unstructured":"Van Lier EA, de Melker HE. Herpes zoster in the Netherlands : Background information for the Health Council. RIVM Report 2018-0110, 2019, https:\/\/doi.org\/10.21945\/RIVM-2018-0110","DOI":"10.21945\/RIVM-2018-0110"},{"key":"1638_CR5","unstructured":"MedPark. Hospital M. Herpes zoster: causes, symptoms, treatments. 2025. https:\/\/www.medparkhospital.com\/en-US\/disease-andtreatment\/herpes-zoster-shingles Accessed 13 Apr 2025."},{"key":"1638_CR6","unstructured":"Netherlands Institute for Health Services Research (Nivel). Nivel-cijfers Ziekten op jaarbasis in Nederland: incidentie en prevalentie. 2024. https:\/\/www.nivel.nl\/nl\/zorg-en-ziekte-in-cijfers\/cijfers-ziekten-op-jaarbasis. Accessed 13 Apr 2025."},{"issue":"6","key":"1638_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-004833","volume":"4","author":"K Kawai","year":"2014","unstructured":"Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833. https:\/\/doi.org\/10.1136\/bmjopen-2014-004833.","journal-title":"BMJ Open"},{"issue":"2","key":"1638_CR8","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jaad.2023.03.031","volume":"89","author":"IL Chen","year":"2023","unstructured":"Chen IL, Chiu HY. Association of herpes zoster with COVID-19 vaccination: a systematic review and meta-analysis. J Am Acad Dermatol. 2023;89(2):370\u20131. https:\/\/doi.org\/10.1016\/j.jaad.2023.03.031.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1638_CR9","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1080\/14760584.2022.2036128","volume":"21","author":"CW Chu","year":"2022","unstructured":"Chu CW, Jiesisibieke ZL, Yang YP, Wu PC, Lin HL, Tung TH. Association of COVID-19 vaccination with herpes zoster: a systematic review and meta-analysis. Expert Rev Vaccines. 2022;21(5):601\u20138. https:\/\/doi.org\/10.1080\/14760584.2022.2036128.","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"1638_CR10","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40121-024-00924-3","volume":"13","author":"R Parikh","year":"2024","unstructured":"Parikh R, Yousefi M, Curran D, Widenmaier R. The impact of the COVID-19 pandemic on the incidence of herpes zoster: a narrative literature review. Infect Dis Ther. 2024;13(3):447\u201361. https:\/\/doi.org\/10.1007\/s40121-024-00924-3.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"1638_CR11","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s40001-023-01238-9","volume":"28","author":"A Shafiee","year":"2023","unstructured":"Shafiee A, Amini MJ, Arabzadeh Bahri R, Jafarabady K, Salehi SA, Hajishah H, et al. Herpesviruses reactivation following COVID-19 vaccination: a systematic review and meta-analysis. Eur J Med Res. 2023;28(1):278. https:\/\/doi.org\/10.1186\/s40001-023-01238-9.","journal-title":"Eur J Med Res"},{"issue":"5","key":"1638_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29629","volume":"96","author":"F Wang","year":"2024","unstructured":"Wang F, Gao Y, Wagner AL, Lu Y. A systematic review and meta-analysis of herpes zoster occurrence\/recurrence after COVID-19 infection and vaccination. J Med Virol. 2024;96(5):e29629. https:\/\/doi.org\/10.1002\/jmv.29629.","journal-title":"J Med Virol"},{"key":"1638_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2022.100393","volume":"21","author":"EYF Wan","year":"2022","unstructured":"Wan EYF, Chui CSL, Wang Y, Ng VWS, Yan VKC, Lai FTT, et al. Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccination: a self-controlled case series and nested case-control study. Lancet Reg Health West Pac. 2022;21:100393. https:\/\/doi.org\/10.1016\/j.lanwpc.2022.100393.","journal-title":"Lancet Reg Health West Pac"},{"issue":"7","key":"1638_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad274","volume":"10","author":"C Ishiguro","year":"2023","unstructured":"Ishiguro C, Mimura W, Uemura Y, Maeda M, Murata F, Fukuda H. Multiregional population-based cohort study for evaluation of the association between herpes zoster and mRNA vaccinations for severe acute respiratory syndrome coronavirus-2: the VENUS study. Open Forum Infect Dis. 2023;10(7):ofad274. https:\/\/doi.org\/10.1093\/ofid\/ofad274.","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"1638_CR15","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1093\/infdis\/jiad297","volume":"228","author":"JG Yoon","year":"2023","unstructured":"Yoon JG, Kim YE, Choi MJ, Choi WS, Seo YB, Jung J, et al. Herpes zoster reactivation after mRNA and adenovirus-vectored coronavirus disease 2019 vaccination: analysis of National Health Insurance Database. J Infect Dis. 2023;228(10):1326\u201335. https:\/\/doi.org\/10.1093\/infdis\/jiad297.","journal-title":"J Infect Dis"},{"issue":"11","key":"1638_CR16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.42240","volume":"5","author":"I Akpandak","year":"2022","unstructured":"Akpandak I, Miller DC, Sun Y, Arnold BF, Kelly JD, Acharya NR. Assessment of herpes zoster risk among recipients of COVID-19 vaccine. JAMA Netw Open. 2022;5(11):e2242240. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.42240.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"1638_CR17","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1080\/14760584.2023.2232451","volume":"22","author":"A Florea","year":"2023","unstructured":"Florea A, Wu J, Qian L, Lewin B, Sy LS, Lin IC, et al. Risk of herpes zoster following mRNA COVID-19 vaccine administration. Expert Rev Vaccines. 2023;22(1):643\u20139. https:\/\/doi.org\/10.1080\/14760584.2023.2232451.","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"1638_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyaf017","volume":"54","author":"JW Vanhommerig","year":"2025","unstructured":"Vanhommerig JW, Verheij RA, Hek K, Ramerman L, Hooiveld M, Veldhuijzen NJ, et al. Data resource profile: Nivel Primary Care Database (Nivel-PCD), the Netherlands. Int J Epidemiol. 2025;54(2):dyaf017. https:\/\/doi.org\/10.1093\/ije\/dyaf017.","journal-title":"Int J Epidemiol"},{"key":"1638_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/clep.S389598","volume":"15","author":"JA Overbeek","year":"2023","unstructured":"Overbeek JA, Swart KMA, Houben E, van Penning- Beest FJA, Herings RMC. Completeness and representativeness of the PHARMO general practitioner (GP) data: a comparison with national statistics. Clin Epidemiol. 2023;15:1\u201311. https:\/\/doi.org\/10.2147\/clep.S389598.","journal-title":"Clin Epidemiol"},{"key":"1638_CR20","unstructured":"Huisman C. Percentage gevaccineerden dat data wil delen met RIVM daalt onder de kritische grens van 95 procent. 2021. https:\/\/www.volkskrant.nl\/nieuws-achtergrond\/percentage-gevaccineerden-dat-data-wil-delen-met-rivm-daaltonder-de-kritische-grens-van-95-procent~bbe45557\/. Accessed 13 Apr 2025."},{"key":"1638_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2022.113008","volume":"164","author":"S Seneff","year":"2022","unstructured":"Seneff S, Nigh G, Kyriakopoulos AM, McCullough PA. Innate immune suppression by SARS-CoV-2 mRNA vaccinations: the role of G-quadruplexes, exosomes, and microRNAs. Food Chem Toxicol. 2022;164:113008. https:\/\/doi.org\/10.1016\/j.fct.2022.113008.","journal-title":"Food Chem Toxicol"},{"issue":"1","key":"1638_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10238-023-01263-2","volume":"24","author":"F Nelli","year":"2024","unstructured":"Nelli F, Fabbri A, Virtuoso A, Giannarelli D, Marrucci E, Fiore C, et al. Herpes zoster after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: a prospective study. Clin Exp Med. 2024;24(1):13. https:\/\/doi.org\/10.1007\/s10238-023-01263-2.","journal-title":"Clin Exp Med"},{"issue":"7830","key":"1638_CR23","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","volume":"586","author":"MJ Mulligan","year":"2020","unstructured":"Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586(7830):589\u201393. https:\/\/doi.org\/10.1038\/s41586-020-2639-4.","journal-title":"Nature"},{"key":"1638_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.975980","volume":"12","author":"JD Benitez Fuentes","year":"2022","unstructured":"Benitez Fuentes JD, Mohamed Mohamed K, de Luna Aguilar A, Jimenez Garcia C, Guevara-Hoyer K, Fernandez-Arquero M, et al. Evidence of exhausted lymphocytes after the third anti-SARS-CoV-2 vaccine dose in cancer patients. Front Oncol. 2022;12:975980. https:\/\/doi.org\/10.3389\/fonc.2022.975980.","journal-title":"Front Oncol"},{"issue":"1","key":"1638_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70071","volume":"34","author":"SH Bots","year":"2025","unstructured":"Bots SH, Brown J, Wong AYS, Martin I, Douglas I, Klungel OH, et al. Core concepts: self-controlled designs in pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2025;34(1):e70071. https:\/\/doi.org\/10.1002\/pds.70071.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"1638_CR26","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/pds.5227","volume":"30","author":"SM Cadarette","year":"2021","unstructured":"Cadarette SM, Maclure M, Delaney JAC, Whitaker HJ, Hayes KN, Wang SV, et al. Control yourself: ISPE-endorsed guidance in the application of self-controlled study designs in pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2021;30(6):671\u201384. https:\/\/doi.org\/10.1002\/pds.5227.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"1638_CR27","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3945\/ajcn.115.113548","volume":"102","author":"DL Streiner","year":"2015","unstructured":"Streiner DL. Best (but oft-forgotten) practices: the multiple problems of multiplicity-whether and how to correct for many statistical tests. Am J Clin Nutr. 2015;102(4):721\u20138. https:\/\/doi.org\/10.3945\/ajcn.115.113548.","journal-title":"Am J Clin Nutr"},{"key":"1638_CR28","unstructured":"RIVM. Deelname COVID-19-vaccinatie in Nederland. 2022. https:\/\/www.rivm.nl\/sites\/default\/files\/2022-03\/COVID-19_Vaccinatie_Schattingen_WebSite_rapport_20220228_1101_def.pdf09-. Accessed 9 May 2025."},{"key":"1638_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2020.104306","volume":"126","author":"EJ Berlinberg","year":"2020","unstructured":"Berlinberg EJ, Kim E, Deiner MS, Patterson C, Porco TC, Acharya NR. Seasonality of herpes zoster and herpes zoster ophthalmicus. J Clin Virol. 2020;126:104306. https:\/\/doi.org\/10.1016\/j.jcv.2020.104306.","journal-title":"J Clin Virol"},{"key":"1638_CR30","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2147\/CLEP.S247575","volume":"12","author":"JG Kuiper","year":"2020","unstructured":"Kuiper JG, Bakker M, van Penning- Beest FJA, Herings RMC. Existing data sources for clinical epidemiology: the PHARMO Database Network. Clin Epidemiol. 2020;12:415\u201322. https:\/\/doi.org\/10.2147\/CLEP.S247575.","journal-title":"Clin Epidemiol"},{"key":"1638_CR31","unstructured":"Heins M, Bes J, Weesie Y, Davids R, Winckers M, Korteweg L, et al. Zorg door de huisarts. Nivel Zorgregistraties Eerste Lijn: jaarcijfers 2022 en trendcijfers 2018-2022. Utrecht: Nivel, 2023. 175 p. https:\/\/www.nivel.nl\/nl\/publicatie\/zorg-door-de-huisarts-nivel-zorgregistraties-eerste-lijnjaarcijfers-2022-en"},{"key":"1638_CR32","doi-asserted-by":"publisher","unstructured":"RIVM & NIVEL-rapport 2021-0227; Lambooij MSH, Janssen M, Meijer LM, Vader S, de Jong S. Het mijden van huisartsenzorg tijdens de coronapandemie: inzicht in verminderde huisartsenzorg tijdens de coronapandemie. 2022. https:\/\/doi.org\/10.21945\/RIVM-2021-0227","DOI":"10.21945\/RIVM-2021-0227"},{"key":"1638_CR33","doi-asserted-by":"publisher","first-page":"1644680","DOI":"10.3389\/fdsfr.2025.1644680","volume":"5","author":"F van Hunsel","year":"2025","unstructured":"van Hunsel F, Kant A. A national pharmacovigilance centre perspective on pandemic preparedness: lessons learned from the COVID-19 pandemic. Front Drug Saf Regul. 2025;5:1644680. https:\/\/doi.org\/10.3389\/fdsfr.2025.1644680.","journal-title":"Front Drug Saf Regul"},{"key":"1638_CR34","unstructured":"RIVM. Gordelroos vaccinatie. 2025. https:\/\/www.rivm.nl\/gordelroos\/gordelroosvaccinatie. Accessed 1 Oct 2025."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01638-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-025-01638-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01638-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T10:15:10Z","timestamp":1776334510000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-025-01638-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1638"],"URL":"https:\/\/doi.org\/10.1007\/s40264-025-01638-2","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"26 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors Rana Jajou, Erik Mulder and Agnes Kant have no conflicts of interest. Karik Hek received funding from Pfizer for research (starting per 01 December 2024) not related to this study. Jetty Overbeek is an employee of the PHARMO Institute for Drug Outcomes Research. This independent research institute performs financially supported studies for government and related health care authorities and several pharmaceutical companies. Florence van Hunsel and Eug\u00e8ne van Puijenbroek are Editorial Board members of\n                      Drug Safety\n                      . These authors were not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All data were anonymized before it was received for data-analyses. For observational studies containing no directly identifiable data, it is not obligated to obtain approval by a medical ethics committee (Dutch Civil Law, Article 7: 458). The study was approved according to the governance code of Nivel-PCD (nr. NZR-00322.008) and by the institutional review board of STIZON, Utrecht, the Netherlands (nr. CC2022-13).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"For observational studies containing no directly identifiable data, it is not obligated to obtain informed consent from patients (Dutch Civil Law, Article 7: 458).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data for this study are not publicly available in order to protect patient privacy . Inquiries about the data used can be sent to the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"R codes cannot be made available due to the data protection policy for this study.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors (RJ, EP, JO, KH, EM, FH and AK) contributed to the design of the study; RJ and EM performed the data-analysis. All authors contributed to the interpretation of data for the work; FH and RJ drafted the work; All authors contributed to reviewing it critically for important intellectual content; All authors read and approved the final version; All authors are in agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author\u2019s contributions"}}]}}